title: Clinical, histopathological, and molecular features of mucosa-associated lymphoid tissue (MALT) lymphoma carrying the t(X;14) (p11;q32)/GPR34-immunoglobulin heavy chain gene.
authors.affiliation: a Department of Hematology , Tenri Hospital , Tenri , Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Akasaka
authors.affiliation: b School of Pharmacy , University of Bradford , Bradford , UK.
authors.forename: Yin-Fai
authors.initials: YF
authors.lastname: Lee
authors.affiliation: c Division of Hematology , Mayo Clinic , Rochester , MN , USA.
authors.forename: Anne J
authors.initials: AJ
authors.lastname: Novak
authors.affiliation: d Diagnostic Pathology , Tenri Hospital , Tenri , Japan.
authors.forename: Gen
authors.initials: G
authors.lastname: Honjo
authors.affiliation: e Laboratory of Cytogenetics, Tenri Institute of Medical Research , Tenri , Japan.
authors.forename: Kayo
authors.initials: K
authors.lastname: Takeoka
authors.affiliation: e Laboratory of Cytogenetics, Tenri Institute of Medical Research , Tenri , Japan.
authors.forename: Fumiyo
authors.initials: F
authors.lastname: Maekawa
authors.affiliation: e Laboratory of Cytogenetics, Tenri Institute of Medical Research , Tenri , Japan.
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Fukutsuka
authors.affiliation: e Laboratory of Cytogenetics, Tenri Institute of Medical Research , Tenri , Japan.
authors.forename: Masahiko
authors.initials: M
authors.lastname: Hayashida
authors.affiliation: a Department of Hematology , Tenri Hospital , Tenri , Japan.|e Laboratory of Cytogenetics, Tenri Institute of Medical Research , Tenri , Japan.
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Ohno
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002883:Chromosomes, Human, Pair 14; D041321:Chromosomes, Human, X; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005091:Exons; D005260:Female; D050438:Genes, Immunoglobulin Heavy Chain; D005820:Genetic Testing; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000175:diagnosis* / Q000235:genetics* / Q000628:therapy; D008297:Male; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D049312:Receptors, Lysophospholipid / Q000235:genetics*; D000069283:Rituximab; D017422:Sequence Analysis, DNA; D014178:Translocation, Genetic; D016896:Treatment Outcome; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C118065:G-protein-coupled receptor 34; C571759:R-CHOP protocol; D049312:Receptors, Lysophospholipid; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone